-+ 0.00%
-+ 0.00%
-+ 0.00%

ZAI LAB RECEIVES U.S. FDA FAST TRACK DESIGNATION FOR ZOCILURTATUG PELITECAN (ZOCI), A DLL3-TARGETING ADC, FOR TREATMENT OF EXTRAPULMONARY NEUROENDOCRINE CARCINOMAS (EPNECS)

Reuters·05/11/2026 11:00:01

Please log in to view news